LabCorp® Plasma Focus™
LabCorp® Plasma Focus™ is an FDA-authorized, next-generation sequencing-based in vitro diagnostic device designed for liquid biopsy profiling of advanced cancers. It detects a wide range of genetic alterations, including SNVs, indels, amplifications, and translocations across 33 genes.
My work involved applying advanced statistical methods for multiple key studies, focusing on the sensitivity and specificity of the assay to test and validate the robustness of the elio™ platform.
01
06/2024
02
Tissue of Origin
05/2024
Utilizing a dataset that encapsulates 21 unique cancer types, this tissue of origin project applies SVM machine-learning techniques to classify cancers based on their gene expression profiles.
This project draws inspiration from research detailed in the paper "Identification of Tumor Tissue of Origin with RNA-Seq Data and Using Gradient Boosting Strategy"
published by BioMed Research International.
03
Ironman Retrospective
01/2024
Ongoing analysis of the Ironman event I performed in Lake Placid on 07/23/2023. This retrospective explores the intersection of intense physical endurance and wearable technology. I start by sharing my experience of the race as well as my training regimen, then go into detail about the metrics captured during preparation for the race, and finally analyze the result for a ~7-month training cycle.
Subsequently; Genetic markers such as VO2 max, lactate threshold, and recovery speed can impact performance in endurance sports. The current goal is to implement these metrics to interpret race results, pacing strategy, and nutrition plan.
